These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30945322)

  • 1. Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients.
    Svedberg A; Vikingsson S; Vikström A; Hornstra N; Kentson M; Branden E; Koyi H; Bergman B; Gréen H
    Br J Clin Pharmacol; 2019 Aug; 85(8):1704-1709. PubMed ID: 30945322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
    Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer.
    Ohgami M; Kaburagi T; Kurosawa A; Homma M
    Lung Cancer; 2016 Nov; 101():9-10. PubMed ID: 27794414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
    Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
    Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.
    Bigot F; Boudou-Rouquette P; Arrondeau J; Thomas-Schoemann A; Tlemsani C; Chapron J; Huillard O; Cessot A; Vidal M; Alexandre J; Blanchet B; Goldwasser F
    Invest New Drugs; 2017 Apr; 35(2):242-246. PubMed ID: 27796680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
    Endo-Tsukude C; Sasaki JI; Saeki S; Iwamoto N; Inaba M; Ushijima S; Kishi H; Fujii S; Semba H; Kashiwabara K; Tsubata Y; Hayashi M; Kai Y; Saito H; Isobe T; Kohrogi H; Hamada A
    Biol Pharm Bull; 2018; 41(1):47-56. PubMed ID: 29311482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
    Deeken JF; Beumer JH; Anders NM; Wanjiku T; Rusnak M; Rudek MA
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):813-9. PubMed ID: 26330331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid high performance liquid chromatography method for erlotinib quantification in vitro: Application to study the effect of resveratrol on metabolism and cellular uptake of erlotinib.
    Zayed A; Al Hroot J; Mayyas A; Al-Husein B
    Fundam Clin Pharmacol; 2023 Oct; 37(5):983-993. PubMed ID: 37143385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.
    van Leeuwen RW; Peric R; Hussaarts KG; Kienhuis E; IJzerman NS; de Bruijn P; van der Leest C; Codrington H; Kloover JS; van der Holt B; Aerts JG; van Gelder T; Mathijssen RH
    J Clin Oncol; 2016 Apr; 34(12):1309-14. PubMed ID: 26858332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects.
    Hamilton M; Wolf JL; Drolet DW; Fettner SH; Rakhit AK; Witt K; Lum BL
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):613-21. PubMed ID: 24474302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.
    Skoglund K; Richter J; Olsson-Strömberg U; Bergquist J; Aluthgedara W; Ubhayasekera SJ; Vikingsson S; Svedberg A; Söderlund S; Sandstedt A; Johnsson A; Aagesen J; Alsenhed J; Hägg S; Peterson C; Lotfi K; Gréen H
    Ther Drug Monit; 2016 Apr; 38(2):230-8. PubMed ID: 26693810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of plasma lenvatinib concentrations and endogenous urinary cytochrome P450 3A activity biomarkers in clinical practice.
    Kumondai M; Ogawa R; Hayashi N; Ishida Y; Oshikiri H; Sato Y; Kikuchi M; Sato Y; Sato T; Maekawa M; Mano N
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1241. PubMed ID: 38992911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 3A selectively affects the pharmacokinetic interaction between erlotinib and docetaxel in rats.
    Qin X; Lu J; Wang P; Xu P; Liu M; Wang X
    Biochem Pharmacol; 2017 Nov; 143():129-139. PubMed ID: 28716728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Drug Monitoring of Erlotinib in Non-Small Cell Lung Carcinoma: A Case Study.
    Catalán-Latorre A; Sureda M; Brugarolas-Masllorens A; Escudero-Ortiz V
    Ther Drug Monit; 2021 Aug; 43(4):447-450. PubMed ID: 33840795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.
    Morcos PN; Cleary Y; Guerini E; Dall G; Bogman K; De Petris L; Viteri S; Bordogna W; Yu L; Martin-Facklam M; Phipps A
    Clin Pharmacol Drug Dev; 2017 May; 6(3):280-291. PubMed ID: 27545757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
    Yamamoto N; Goto K; Nishio M; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Tajima K; Tamura T
    Int J Clin Oncol; 2017 Feb; 22(1):70-78. PubMed ID: 27659294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.
    Rakhit A; Pantze MP; Fettner S; Jones HM; Charoin JE; Riek M; Lum BL; Hamilton M
    Eur J Clin Pharmacol; 2008 Jan; 64(1):31-41. PubMed ID: 18000659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Emoto-Yamamoto Y; Iida S; Kawanishi T; Fukuoka M
    J Clin Pharm Ther; 2015 Apr; 40(2):232-9. PubMed ID: 25402940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
    Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.